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diverse cell types distinguishes MAPC from Mesenchymal Stem
Cells (MSC), and suggests that MAPCs may therefore be an ideal
cell for in vivo therapies for tissue repair or regeneration in mul-
tiple organ systems (Jiang Y et al Nature, 2002; 418:41–49). We
have developed the technology for the large-scale expansion of
MAPC with stable phenotype and biological properties. Under
these conditions, cell surface marker analysis of MAPC revealed
that these cells are positive for CD10, CD90, and CD49c, they are
weakly positive for MHC class I, and are negative for MHC class
II, CD45, and CD106, indicating that MAPC are not derived from
the hematopoietic lineage. However, to optimize in vivo utiliza-
tion, the understanding of immunological properties of MAPC is
critical. Thus, we undertook an analysis of MAPC immunogenic-
ity. First, these stem cells were shown to be non-immunogenic as
MAPC from two different rat strains did not stimulate allogeneic T
cell proliferation, while splenocytes of the same rat strains elicited
strong proliferative responses in a mixed lymphocytic culture.
Second, MAPC displayed immunosuppressive properties. Addition
of MAPC at the initiation of a mixed lymphocyte reaction (MLR)
suppressed T cell proliferation in a dose dependent manner. The
inhibition was detectable when number as low as 3000 MAPC/well
were added to 1 105 T cell responder. Lymphocyte proliferation
in MAPC-containing cultures was inhibited by up to 80% when
compared to cultures without MAPC. The ability to inhibit T cell
alloresponse was independent of the MHC, allowing the use of
third party MAPC as inhibitory cells. MAPC also inhibited pro-
liferative responses to the T cell mitogen Concanavalin A (50%),
although inhibition required higher MAPC:responder cell ratios.
Taken together, these data suggest that MAPC are progenitor cells
that do not express markers of the hematopoietic lineage; they are
non-immunogenic to T cells, suggesting that universal MAPC
donors may be used for tissue repair or regeneration; and MAPC
exhibit potent immunosuppressive properties, a result which sug-
gests that these calls may be useful in the management and/or
prevention of GVHD.
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Mesenchymal stem cells (MSC), as well as showing promise for
tissue regeneration and gene therapies, have the potential to facil-
itate bone marrow transplantation. First, they can provide stromal
support for engrafted cells, and second, their immunologic prop-
erties may facilitate engraftment and reduce graft versus host
disease. Much is made of the ease with which MSC can be cultured
and expanded many-fold in vitro, however there is evidence that
this can alter the fundamental properties of these cells. Therefore,
we have explored the potential to increase the number of marrow
MSC in vivo using various cytokine regimens in a nonhuman
primate (NHP) model. Male baboons between 7 and 11 years of
age received subcutaneous cytokines as follows: (1) G-CSF 100
mcg/kg/day for 5 days; (2) pegylated G-CSF (pegG-CSF), single
dose 300 mcg/kg day 5; (3) G-CSF 100 mcg/kg/day  stem cell
factor (SCF) 50 mcg/kg/day for 5 days; and (4) pegylated
megakaryocyte growth and development factor (pegMGDF) 1
mcg/kg second daily for 10 days  G-CSF 100 mcg/kg/day for 5
days starting day 5 before the harvest. Bone marrow was aspi-
rated from the iliac crest at baseline and on the ﬁnal day of cytokine
administration. Mononuclear cells were isolated on Ficoll-Paque
Plus, and plated in triplicate in alpha-MEM plus 20% FCS for
ﬁbroblast colony forming cells (CFU-F). Cells were ﬁxed, stained,
and scored on day 7, and the number of CFU-F/mL of bone
marrow was then calculated. The mean baseline CFU-F marrow
concentration was 2 032/mL (n  15). There was an increase in
CFU-Fs following each of the cytokine regimens to 11 427/mL, 8
430/mL, 20 662/mL, and 15 745/mL after G-CSF (n  3, P 
.001), pegG-CSF (n 4, P	 .05), G-CSFSCF (n 5, P .001),
and G-CSFpegMGDF (n  4, P  .01) compared to baseline,
respectively. We also explored the potential for the mobilization of
MSC into peripheral blood. CFU-F were not detected in baseline
peripheral blood mononuclear cells (PBMNC) samples from any
animal. However, CFU-F were detected in 3 animals after
G-CSFSCF at a frequency of 0.8/mL to 1.5/mL, but no other
cytokine regimen. In conclusion, these data conﬁrm that cytokine
regimens used to mobilize hemopoietic stem cells can be used to
induce in vivo expansion and mobilization of MSC and that the
combination of G-CSF and SCF may be the most effective.
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MODULATION OF ALDEHYDE DEHYDROGENASE ACTIVITIY AND RETI-
NOID SIGNALING INDUCES HEMATOPOIETIC STEM CELL SELF RE-
NEWAL
Muramoto, G.1, Saﬁi, R.1, Chao, N.J.1, Colvin, M.1, McDonnell, D.1,
Chute, J.P.1 Duke University, Durham, NC.
Aldehyde dehydrogenases are cytosolic enzymes that convert
aldehydes into carboxylic acids. Human aldehyde dehydrogenase 1
(ALDH1) is highly expressed in the liver and in hematopoietic
stem cells (HSCs). Although ALDH1 is a selectable marker of
HSCs, its HSC-speciﬁc function is unknown. We hypothesized
that ALDH might play a critical role in HSC fate determinations
since it is required for the production of retinoic acids, which are
broadly implicated in tissue differentiation, tissue patterning, and
embryonic development in vertebrates. In this study, highly puri-
ﬁed human CD34CD38lin HSCs were cultivated with early
acting cytokines, thrombopoietin, stem cell factor, and Flt-3 ligand
(TSF) in the presence or absence of the competitive ALDH inhib-
itor, diethylaminobenzaldehyde (DEAB). Treatment of human
BM and CB HSCs with TSF caused a loss of CD34CD38 cells
in culture, morphologic differentiation, ampliﬁcation of commit-
ted colony forming cells (CFCs), and a loss of primitive cells
capable of repopulating non-obese diabetic/severe combined im-
munedeﬁcient mice (SCID-Repopulating Cells, SRCs). Con-
versely, culture of BM and CB HSCs with TSF plus 100 M
DEAB blocked the morphologic differentiation and lineage com-
mitment of HSCs in culture, expanded the CD34CD38 pop-
ulation, and ampliﬁed SRCs 2- to 4-fold compared to input, indi-
cating a fundamental role for ALDH activity in HSC
differentiation. The effects of DEAB could be reversed by the
co-administration of the retinoic acid receptor (RAR) agonist,
all-trans retinoic acid (ATRA), suggesting that the ability of
ALDH to produce retinoic acids is important in determining HSC
fate. Via screening studies of direct ligands of RAR and RXR, we
also identiﬁed a selective RXR modulator, LGD101506, which
functioned similarly to DEAB in impeding HSC differentiation
and causing the 4-fold expansion of SRCs. Interestingly, both
DEAB treatment and LGD101506 reversed the down-modulation
of HOXB4 transcription that was otherwise observed in
CD34CD38lin cells during culture with cytokines, suggest-
ing that inhibition of ALDH or RXR modulation may promote
HSC self-renewal via discrete interactions with other regulatory
pathways. Modulation of ALDH activity and retinoid signaling is a
novel and effective strategy to amplify human HSCs.
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DEXAMETHASONE ENHANCES ERYTHROPOIETIC DIFFERENTIATION OF
EMBRYONIC STEM CELLS
Srivastava, A.S.1, Kaushal, S.1, Carrier, E.1 University of California
San Diego, La Jolla, CA.
We have studied the in vitro differentiation of murine embryonic
stem cells (ES) towards erythropoiesis and expression of genes
during this process. It has been reported that dexamethasone di-
rects ES cells towards erythrocytic differentiation but the mecha-
nism of gene regulation induced by dexamethasone is not well
understood. We hypothesized that dexamethasone induces up-
regulation of erythropoietic genes such as GATA-1, FLK-1,
EPO-R, and directs ES cells towards erythropoietic differentiation.
Poster Session II
107BB&MT
Murine ES cells (129 CCE) obtained from Dr. Nagy laboratory,
Canada, were subjected to the in vitro primary hematopoietic
differentiation media containing methylcellulose, IMDM, IL -3,
IL-6, and SCF (stem cell factor) without LIF (leukemia inhibitory
factor) to promote embryoid body (EB) formation. Total RNA was
collected on day 3, 5, and 9 EBs for gene expression studies using
RT-PCR. On day 9, EBs were subjected to secondary differenti-
ation using three different cytokines and growth factors combina-
tion, (1) SCF, EPO, dexamethasone, IGF, (2) SCF, IL-3, IL-6,
TPO, (3) SCF IL-3, IL-6, TPO, EPO. Total RNA from day12 of
secondary differentiated ES cells was collected to study cytokines
and growth factors dependent erythrocytic differentiation and gene
regulation, using RT-PCR. Our results demonstrate upregulation
of Gata-1, Flk-1, HoxB-4, Epo-R, and globin genes (
-globin,
BH-1 globin, b-major globin, e-globin, and z-globin) in the 9 days
old EBs, whereas RNA collected from 5 days old EBs showed
expression of HoxB-4, e-globin, -globin, BH1-globin, and
FLK-1. Three days old EBs showed only HoxB-4 and FLK-1 gene
expression and lack of expression of globin genes, indicating that
erythropoiesis-speciﬁc genes and hemoglobin switch activate later.
Gene expression studies of RNA collected from secondary differ-
entiated ES cells and media containing dexamethasone showed
downregulation of GATA-3 and upregulation of GATA-1, Flk-1,
and Epo-R in comparison to the two other cytokines and growth
factors media combination. These results conﬁrm our hypothesis
that dexamethasome induces erythropoiesis by downregulating
GATA 3 and upregulating erythropoietic genes such as
GATA-1, Flk-1, and Epo-R. The morphological characteristics of
cells after secondary differentiation showed enhanced production
of erythrocytic precursors in dexamethasone containing media,
which corresponded with molecular studies.
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Background: Mesenchymal stem cells (MSCs) are important com-
ponent of the bone marrow microenvironment and are progenitors of
mesenchymal tissues. The effect of therapeutic irradiation to MSCs
remains unexplored. Materials and Methods: MSCs were derived
from healthy donors. Effects of irradiation with single dose (dosage
ranges 2, 4, 6, 8, 12 Gy) on human MSCs were investigated. Post-
irradiation cell proliferation was assessed by XTT assay and cell
counting. Osteogenic and adipogenic differentiation function were
evaluated after irradiation. ALP activity and calcium deposition in
irradiated MSCs were quantiﬁed following osteogenic induction. Re-
sults: Irradiation inhibited proliferation of human MSCs up to 2
weeks post-irradiation but thereafter, survival cells regained normal
proliferation rate back to the control level. ALP activity and calcium
deposition were both reduced in a dose-dependant fashion. Maximum
reduction (16% of control ALP activity and 9% of control calcium
level) was noted in MSCs under 12 Gy irradiation. Adipocyte per-
centage was reduced by 50% in cultures that received irradiation 	4
Gy. Attempts to protect the irradiated cells with 1 M all-trans
retinoic acid showed no protective effect on MSCs proliferation and
differentiation. Conclusion: Irradiation damaged the capacity of hu-
man MSCs proliferation and differentiation. However, full recovery
of growth and renewal ability was observed in surviving MSCs after 2
weeks.
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CORD BLOOD EXPANSION WITH SELECTIVE DEPLETION OF CD52
POSITIVE CELLS USING CAMPATH-1H: INCREASED CD34 CELLS AND
MEGAKARYOCYTIC PROGENITORS
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The overgrowth of mature haematopoietic cells leads to a reduc-
tion of the long term proliferative potential of cord blood expan-
sion cultures. We postulated that the depletion of CD52 positive
cells in these cultures could lead to a higher percentage of imma-
ture progenitors including CD34 positive cells and megakaryocyte
progenitors. Immunomagnetic isolation of CD34 cells was per-
formed on leukocyte enriched cord blood samples, followed by
culture in SFEM serum free medium in the presence of 50 mg/ml
of: stem cell factor (SCF); Flt3-ligand and thrombopoietin (Tpo)
for up to 14 days. Well-demarcated populations of CD52 and
CD34 positive cells were found on ﬂow cytometric analysis. Phar-
maceutical-grade humanized anti-CD52 monoclonal antibody
Campath-1H was used, in the presence of complement, to deplete
CD52 positive cells during the cord blood expansion cultures.
Addition of the antibody resulted in a signiﬁcant reduction of
CD52 positive cells in the cord blood cultures versus cells grown in
culture without anti-CD52 antibodies (CD52 cells 0.64% with
Campath-1H versus 13.76% in cultures without the antibody
added). The percentage of CD34 positive cells (7.13% with Cam-
path-1H versus 1.04% in cultures without antibody) and
megakaryocyte progenitors after 3 weeks of cultures were also
higher in Campath-1H treated cord blood cultures. The differ-
ences were more pronounced when Interleukin-3 (IL3) was added
to the cytokine cocktail for cord blood expansion. We conclude
that anti-CD52 antibodies may be used to deplete mature cells
from cord blood cultures resulting in a signiﬁcantly higher per-
centage of immature CD34 positive cells and megakaryocytic pro-
genitors.
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MEASUREMENT OF MORTALITY IN LONG-TERM HEMOPOIETIC STEM
CELL TRANSPLANT SURVIVORS
Nivison-Smith, I.1, Bradstock, K.F.2, Dodds, A.J.3, Ma, D.D.F.3,
Szer, J.4 1. Australasian Bone Marrow Transplant Recipient Registry
(ABMTRR), Darlinghurst, NSW, Australia; 2. Westmead Hospital,
Westmead, NSW, Australia; 3. St Vincent’s Hospital, Darlinghurst,
NSW, Australia; 4. Royal Melbourne Hospital, Parkville, Victoria,
Australia.
Aim: To measure mortality rates in long-term hemopoietic stem
cell transplant survivors and compare these with the general pop-
ulation. Method: Records of patients who had survived more than
2 years post autologous or allogeneic stem cell transplant were
drawn from the ABMTRR database. Annual mortality was calcu-
lated for this group and compared to the mortality of the Australian
population using indirect age-standardized mortality rates. Re-
sults: Among 1502 allogeneic recipients disease free at 2 years,
there were 36 deaths (18 from non-malignancy related causes) in
the third year compared to an expected 3. Among 778 allogeneic
recipients disease free at 5 years, there were 3 deaths in the sixth
year deaths (2 from non-malignancy related causes) compared to
an expected 1. In contrast, among 2741 autologous recipients
disease free at 2 years, there were 52 deaths (8 from non-malig-
nancy related causes) in the third year compared to an expected 9.
Among 1188 autologous recipients disease free at 5 years, there
were 14 deaths in the sixth year (6 non-malignancy) compared to
an expected 3.Conclusion:The non-malignancy mortality of both
allogeneic and autologous HSCT recipients approaches population
norms for those who survive more than 5 years post transplant.
Indirect age-standardized mortality calculations offer a relatively
straightforward mortality analysis strategy. The ABMTRR is an
important national data resource providing timely information on
transplant activity and outcome across Australia and New Zealand.
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LONG-TERM OUTCOME OF ALLOGENEIC STEM CELL TRANSPLANT:
SINGLE INSTITUTION EXPERIENCE OF A LARGE COHORT
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